NeOnc Technologies Holdings, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.26 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 81.03M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Details
| Name | NeOnc Technologies Holdings, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 5 |
| Founded | 2008 |
| Ceo | Amir Heshmatpour |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US64051A1016 |
| Cusip | 64051A101 |
| Cik | 1979414 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Amir Farrokh Heshmatpour | President, Chief Executive Officer, Executive Chairman and Secretary |
| Dr. Thomas C. Chen M.D., Ph.D. | Founder, Chief Medical Officer, Chief Scientific Officer and Vice Chairman |
| Keithly A. Garnett | Chief Financial Officer |
| Dr. Josh Neman-Ebrahim Ph.D. | Chief Clinical Officer |
| David Choi Jr. | Chief Accounting Officer |
Contact
| Address | 23975 Park Sorrento, Suite 205, Calabasas, California 91302, United States |
| Phone | 310 663 7831 |
| Website | https://www.neonc.com |